Shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) have been assigned a consensus rating of “Hold” from the nine brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $4.23.

TTPH has been the subject of a number of research reports. Robert W. Baird reiterated a “buy” rating and set a $3.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Monday, January 7th. B. Riley initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Friday, January 4th. They issued a “buy” rating and a $3.00 price objective for the company. Gabelli lowered shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.40 price objective for the company. in a research report on Friday, March 15th. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 23rd. Finally, Piper Jaffray Companies cut their price objective on shares of Tetraphase Pharmaceuticals from $6.00 to $4.00 and set an “overweight” rating for the company in a research report on Friday, March 15th.

NASDAQ:TTPH traded down $0.03 on Friday, reaching $1.06. 845,590 shares of the company’s stock were exchanged, compared to its average volume of 650,988. The company has a quick ratio of 7.73, a current ratio of 7.78 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $56.97 million, a PE ratio of -0.77 and a beta of 3.00. Tetraphase Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $4.49.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.40). The firm had revenue of $4.28 million during the quarter, compared to analyst estimates of $2.23 million. Tetraphase Pharmaceuticals had a negative net margin of 381.71% and a negative return on equity of 72.26%. Analysts anticipate that Tetraphase Pharmaceuticals will post -1.52 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in shares of Tetraphase Pharmaceuticals by 6.4% in the fourth quarter. Bank of America Corp DE now owns 142,775 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 8,567 shares during the period. Gamco Investors INC. ET AL raised its stake in Tetraphase Pharmaceuticals by 42.9% in the fourth quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 15,000 shares in the last quarter. Rhumbline Advisers raised its stake in Tetraphase Pharmaceuticals by 40.6% in the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 21,089 shares in the last quarter. Geode Capital Management LLC raised its stake in Tetraphase Pharmaceuticals by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 551,837 shares of the biopharmaceutical company’s stock valued at $623,000 after purchasing an additional 21,854 shares in the last quarter. Finally, Alambic Investment Management L.P. raised its stake in Tetraphase Pharmaceuticals by 31.0% in the fourth quarter. Alambic Investment Management L.P. now owns 114,874 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 27,170 shares in the last quarter. Institutional investors own 44.02% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Recommended Story: What is total return in investing?

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.